John N. Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John N. Wang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Bing Rao
Department of Structural Biology, Stanford University, Stanford, CA, USA
1 shared publication- Brian L. Hie
Arc Institute, Palo Alto, CA, USA
1 shared publication - Claudia L. Driscoll
Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UK
1 shared publication - Haoyu Dai
Department of Chemical Engineering, Stanford University, Stanford, CA, USA
1 shared publication Jim L. Zhang
Department of Structural Biology, Stanford University, Stanford, CA, USA
1 shared publicationLiang Feng
Department of Structural Biology, Stanford University, Stanford, CA, USA
1 shared publication
Latest Publications
- Open Access
Efficient generation of epitope-targeted de novo antibodies with Germinal
Obtaining novel antibodies against specific protein targets is a widely important yet experimentally laborious process. Meanwhile, computational methods for antibody design have been limited by low success rates that currently require resource-intensive screening. Here, we introduce Germinal, a broadly enabling generative pipeline that designs antibodies against specific epitopes with nanomolar binding affinities while requiring only low-n experimental testing. Our method co-optimizes antibody structure and sequence by integrating a structure predictor with an antibody-specific protein language model to perform de novo design of functional complementarity-determining regions (CDRs) onto a user-specified structural framework. When tested against four diverse protein targets, Germinal successfully designed functional antibodies across all targets and binder formats, testing only 43-101 designs for each antigen. Validated designs also exhibited robust expression in mammalian cells and high sequence and structural novelty. We provide open-source code and full computational and experimental protocols to facilitate wide adoption. Germinal represents a milestone in efficient, epitope-targeted de novo antibody design, with notable implications for the development of molecular tools and therapeutics.
Open AccessEfficient generation of epitope-targeted de novo antibodies with Germinal
Obtaining novel antibodies against specific protein targets is a widely important yet experimentally laborious process. Meanwhile, computational methods for antibody design have been limited by low success rates that currently require resource-intensive screening. Here, we introduce Germinal, a broadly enabling generative pipeline that designs antibodies against specific epitopes with nanomolar binding affinities while requiring only low-n experimental testing. Our method co-optimizes antibody structure and sequence by integrating a structure predictor with an antibody-specific protein language model to perform de novo design of functional complementarity-determining regions (CDRs) onto a user-specified structural framework. When tested against four diverse protein targets, Germinal successfully designed functional antibodies across all targets and binder formats, testing only 43-101 designs for each antigen. Validated designs also exhibited robust expression in mammalian cells and high sequence and structural novelty. We provide open-source code and full computational and experimental protocols to facilitate wide adoption. Germinal represents a milestone in efficient, epitope-targeted de novo antibody design, with notable implications for the development of molecular tools and therapeutics.